The FDA Told You ZYN Is Safer Than Cigarettes. It Used to Say That About 'Light' Ones, Too.

On June 30, the FDA sent Swedish Match USA — a subsidiary of Philip Morris International — an order authorizing something no nicotine pouch has ever been allowed to say to an American shopper: that ZYN puts users at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis than cigarettes. Twenty products across ten flavors — Cool Mint, Citrus, Coffee, Cinnamon, Menthol, Peppermint, Spearmint, Wintergreen, Chill, and Smooth, each in 3mg and 6mg strengths — can now carry that sentence on the can, in the ad, in the app.

The FDA gave Philip Morris a true claim it will use for an untrue purpose.

That’s the take. Everything else here is the fine print the company would rather you skim past on your way to the shelf.

What the FDA Actually Authorized — and the Sentence It Refused To

A “modified risk tobacco product” order, or MRTP — plain language: a government permission slip to make one specific, narrowly worded health comparison — is not a safety approval, and it is not a claim that ZYN helps anyone quit smoking. The FDA said as much in its own order: there is no safe tobacco product, and quitting nicotine entirely remains the healthiest option. The authorization is genuinely narrow on paper — one sentence, ten flavors, two strengths, five years before it has to be renewed, subject to withdrawal if youth uptake climbs or the population-level math stops working in its favor. It pointedly excludes the fruit flavors kids reach for most: Black Cherry and Peach didn’t make the list.

None of that survives contact with a marketing budget. Philip Morris now gets to print “lower risk of…cancer, heart disease…stroke” on a product a teenager sees a friend using at lunch, sold in a can that looks and tastes almost identical to the fruit flavors the FDA just said no to. The claim is legally precise. The shelf, the ad, and the group chat are not going to carry the footnotes.

The order also landed five weeks after FDA Commissioner Marty Makary resigned, reportedly after the administration pressured him to approve fruit-flavored e-cigarettes he’d been blocking specifically over youth appeal. Whatever internal resistance existed inside FDA’s tobacco center to flavor-adjacent nicotine marketing walked out the door with him. The ZYN order is the same agency, under new leadership, making its next call in the same harm-reduction-framing fight that just lost the one person who kept saying no to it.

460,000 Kids Didn’t Wait Around for FDA Permission

The FDA’s own 2025 National Youth Tobacco Survey, released a week before the ZYN order, found nicotine pouch use among middle and high schoolers has nearly quadrupled since 2022 and now sits at 1.7% of students — roughly 460,000 kids. More than 1 in 6 of them use pouches daily. More than 9 in 10 use flavored versions. ZYN is the brand they name most.

Michael Seilback of the American Lung Association called the decision “appalling,” saying the FDA had authorized “flavors like citrus, cool mint and cinnamon as modified risk tobacco products, which attract kids,” and calling on the agency to reverse it. Dr. Adam Goldstein of UNC’s tobacco intervention program named the gap between the claim and reality in one line: “The majority of people using oral nicotine products are not using them to quit combustible cigarettes.” The modified-risk math only works for a smoker who switches completely. Almost nobody the claim will actually reach fits that description — including nearly half a million teenagers who never smoked a cigarette to begin with.

We Ran This Exact Experiment on “Light” Cigarettes, and Congress Had to Ban the Results

In the 1950s and ’60s, cigarette makers rolled out “filtered” and “light” cigarettes carrying an implicit promise: less tar, less risk, a safer way to keep smoking rather than a reason to stop. Smokers believed it — and compensated, pulling harder, smoking more of each cigarette, covering filter vents with their fingers without realizing it — erasing whatever tar reduction the filter delivered while getting a clean conscience about never quitting. By 2009, the evidence that “light” and “low-tar” language measurably misled smokers without cutting their actual disease risk was strong enough that Congress didn’t just discourage the wording — it banned the descriptors outright in the Family Smoking Prevention and Tobacco Control Act — the same law that created the modified-risk pathway the FDA just used on ZYN. The “safer” claim wasn’t the thing that got a generation of smokers to quit. It was the thing that kept them smoking longer.

The “safer” claim wasn’t the thing that got a generation of smokers to quit.

If You’re the One Using It Tonight, Here’s What the Can Won’t Say

You already know pouches feel different from a cigarette — no smoke, no smell, no coughing, easier to use at your desk or in your car. That’s real, and it’s most of why ZYN caught on with adult smokers trying to get off cigarettes in the first place. What the can won’t tell you is the mechanism Dr. Pamela Ling described to NBC News in plain terms: every time your brain is exposed to nicotine, it builds more nicotine receptors — in plain language, your brain remodels itself to expect the drug — so the amount you need just to feel normal keeps climbing rather than falling. That’s nicotine dependence, mechanically, and a lower-risk delivery method doesn’t slow it down or reverse it.

New research in JAMA Network Open from USC and Truth Initiative shows what that climb looks like in real teenagers: among daily youth vapers, the share who tried to quit and couldn’t rose from 28.2% in 2020 to 53% in 2024, even as the total number of kids vaping fell over the same period. Dr. Abbey Masonbrink of USC’s Keck School of Medicine put it plainly: the ones still vaping are showing “a severe level of nicotine addiction.” Fewer kids are starting. The ones who don’t stop are getting more stuck, not less — and there’s no reason to expect pouches, which carry up to 6 milligrams of nicotine against the 2 to 4 milligrams in a piece of Nicorette gum, to break that pattern instead of joining it.

If quitting nicotine is actually on your list this week, the tools built for that specific job — quitline counseling, clinician-dosed nicotine replacement therapy, prescription cessation medication — are still there tonight, free in most states, regardless of what any can says about cigarettes. That’s not the message the FDA sent this week. It should have been.

The FDA’s order is a careful, scientifically defensible ruling about one narrow comparison: pouches versus cigarettes, for a smoker who switches completely and never looks back. Nobody at Swedish Match is planning to advertise it that narrowly, and nobody covering nicotine and tobacco policy should treat the gap between the claim and the marketing as an accident. We banned “light” for exactly this reason, and the lesson didn’t expire. The industry doesn’t need the whole truth to sell a product. It needs one true sentence, printed big enough to read from across the room.